9 October 2024 US pharma major Bristol Myers Squibb’s recent approval from the US Food and Drug Administration (FDA) for Cobenfy (xanomeline and trospium chloride) for the treatment of adults with schizophrenia is a win for the company.
USA-based biotech Xencor has signed a second strategic research collaboration and commercialization agreement with the University of Texas MD Anderson Cancer Center, this one to develop novel CD3 bispecific antibody therapeutics for the potential treatment of patients with cancer. 7 January 2021
The Gilead Sciences subsidiary Kite has agreed to set up a cell therapy research collaboration with UK-based Oxford BioTherapeutics (OBT). 6 January 2021
UK pharma major AstraZeneca has announced that its COVID-19 vaccine AZD1222 has been granted emergency-use authorization in India, as well as Argentina, Dominican Republic, El Salvador, Mexico and Morocco for the active immunization of adults. 6 January 2021
US rare and orphan diseases drug developer Cerecor has announced results from its exploratory Phase II US-based randomized, double-blind, placebo-controlled proof of concept trial (NCT04412057) of the human anti-LIGHT (TNFSF14) monoclonal antibody (MAb) CERC-002. 6 January 2021
The European Medicines Agency today announced its recommendation for conditional marketing authorization to be granted to another novel coronavirus vaccine. 6 January 2021
US drugmaker AbbVie has announced positive top-line results from two Phase III studies of Skyrizi (risankizumab) in adults with active psoriatic arthritis. 6 January 2021
Eleva GmhH, a Germany-based manufacturer of biologics, has secured up to 60 million euros ($73.7 million) in funding from Zukunftsfonds Heilbronn (ZFHN). 6 January 2021
Specialty biopharma Marius Pharmaceuticals has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) seeking approval of Kyzatrex, its oral testosterone undecanoate soft gelatin capsule for the treatment of primary and secondary hypogonadism in men. 5 January 2021
French oncology-focussed biotech Innate Pharma SA closed up more than 5% at 3.68 euros today, after it revealed that Sanofi has made the decision to progress IPH6101/SAR443579 into investigational new drug (IND)-enabling studies. 5 January 2021
Swiss pharma giant Roche’s novel cancer immunotherapy tiragolumab has been granted Breakthrough Therapy designation (BTD) by the US Food and Drug Administration, in combination with Tecentriq (atezolizumab). 5 January 2021
The US Food and Drug Administration has weighed in on the question of coronavirus vaccine dosing, as health experts and the general public alike discuss the best way to optimise limited supplies. 5 January 2021
As the COVID-19 pandemic raged around the globe last year, biopharma capital markets were robust in 2020, with a record $13.5 billion raised in 81 initial public offerings (IPOs) and $41.1 billion in 256 follow-on offerings (FOs), noted SVB Leerink analyst Geoffrey Porges. 4 January 2021
Days after the UK government announced it would alter the schedule for the country’s coronavirus vaccine program, healthcare experts continue to debate the wisdom of deviating from the approved timeline. 4 January 2021
German privately-held vascular integrity company Adrenomed today revealed that Wolfgang Baiker has been appointed as chief executive (CEO) effective January 1, 2021. 4 January 2021
An Indian government’s expert panel has reportedly recommended approval of the vaccine, developed by AstraZeneca and Oxford University for emergency use in India to provide immunity against COVID-19, according to local media reports. 4 January 2021
Nearly the whole of 2020 was dominated by the impact of the novel coronavirus, but the global biopharmaceutical industry, apart from being instrumental in bringing to market treatments for the symptoms of COVID-19 as well as vaccines to prevent it, continued about its business in difficult times. 1 January 2021
The World Health Organization (WHO) on December 31 listed the Comirnaty COVID-19 mRNA vaccine for emergency use, making the Pfizer/BioNTech vaccine, previously dubbed BNT162b2, the first to receive emergency validation from the WHO since the outbreak began a year ago. 1 January 2021
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Cambridge, USA-based City Therapeutics has announced its launch with a vision to lead the future of RNA interference (RNAi)-based medicine. 9 October 2024
Zephyrm Bioscience, a Cayman Islands-based biotech, has filed for an initial public offering (IPO) in Hong Kong, seeking to raise additional capital to advance its cell therapy pipeline. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
UK-based Mestag Therapeutics has entered into a license and collaboration agreement with Merck & Co to explore new therapeutic options for inflammatory diseases. 8 October 2024
With its recent US Food and Drug Administration (FDA) approval, Eli Lilly’s Ebglyss (lebrikizumab) adds a new competitor to the atopic dermatitis (AD) market. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024
Orchard Therapeutics has signed an exclusive distribution agreement with Turkish drugmaker Er-Kim, for the gene therapy Libmeldy (atidarsagene autotemcel). 7 October 2024
Cambridge, USA-based biotech Judo Bio has announced the company’s launch and $100 million in initial financing, including seed financing and Series A. 7 October 2024
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024